ABL1 TKI Resistance Mutation Detection with Interpretation
Epic code: LAB8915 for Blood
LAB8919 for Bone Marrow
Order form: Comprehensive Hematopathology Requisition
Supply order: Supply Order Form
Billing: Billing Policies
CPT code: 81170
Blood or Bone Marrow Aspirate
Collection Medium:
Pink top tube 6 mL (K2-EDTA)
Whole blood (EDTA anti-coagulated; 6 mL pink top tube) or bone marrow aspirate (EDTA anti-coagulated; pink or lavender top tube).
Rejection Criteria:
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens.
Testing Schedule:
Turn Around Time:
21 days
Reference Range:
No variants detected.
Testing is for detection of ABL1 tyrosine kinase domain mutations that confer resistance to TKI therapy in patients with BCR-ABL1 positive chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).

This assay is not intended to be used for detection or quantification of BCR-ABL1 fusion transcripts.

Testing is recommended for patients who exhibit treatment failure as evidenced by rising BCR-ABL1 fusion transcript levels. A BCR-ABL1 fusion transcript level of 5%IS (percent International Standard) is necessary for testing.

The limit of detection for variants is 1.0% mutant allele fraction.
RNA is isolated from whole blood. Reverse transcription and anchored multiplex PCR are performed for targeted next-generation sequencing (Illumina based sequencing) to detect variants in the ABL1 gene spanning amino acids 85 – 559.
Testing requires dedicated collection tube.
Sample Processing:
Do Not Centrifuge.
Sample Storage:
Transport Instructions:
Place specimen into zip-lock type bag, seal bag.
Recommend early AM overnight shipping or equivalent if not on courier service.
Ship refrigerated.
Place requisition into outside pocket of bag.
Protect phlebotomy tube from excessive heat and ship in cooled container during summer months.
CPT Code: